论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Dupilumab 治疗不同背景下的慢性痒疹:病例系列
Authors Luo N , Wang Q , Lei M, Li T, Hao P
Received 21 June 2022
Accepted for publication 5 September 2022
Published 12 September 2022 Volume 2022:15 Pages 1863—1867
DOI https://doi.org/10.2147/CCID.S379231
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Dr Jeffrey Weinberg
Abstract: Chronic prurigo (CPG) is a chronic inflammatory disease characterized by intense pruritus, and therapy is often challenging due to its unclear pathogenesis. Here, we report four patients with refractory CPG from different backgrounds who experienced failure of conventional therapy and were controlled with dupilumab, accompanied by a significant decrease in pruritus numerical rating scale, dermatology life quality index, and investigator global assessment, without adverse effects. Furthermore, dupilumab improved the condition of asthma in CPG patients along with an increase in asthma control test scores.
Keywords: dupilumab, chronic prurigo, therapy, asthma